Business Wire

MAVENIR/MOBILEDGEX

22.6.2021 15:02:08 CEST | Business Wire | Press release

Share
Mavenir and MobiledgeX Enable Global Edge Connectivity With Deutsche Telekom

Mavenir, in collaboration with MobiledgeX and Deutsche Telekom, have demonstrated and validated the reference design for deploying cloud-native 5G User Plane Function (UPF) to support Multi-Access Edge Computing (MEC) applications, tailored to each use case need for proximity and performance. The reference design is fully cloud-native, abstracted away from underlying cloud architecture, infrastructure vendor and operating owner.

“We are excited to partner with Mavenir and MobiledgeX to demonstrate dynamic cloud-native deployment of 5G Core UPF for users where it is needed. The UPF can run inside the operator’s owned network, inside a private 4G/5G network, inside the roaming network, or in the public cloud. The ability to dynamically and seamlessly orchestrate traffic across our own footprint and the footprint of others opens up the possibility for new connectivity solutions for customers,” says Alex Choi, SVP Strategy & Technology Innovation, Deutsche Telekom.

A service-based, cloud-native UPF is at the core of the reference design. Since the introduction of mobile packet data in 3G, all data traffic, irrespective of source, destination, and requesting application, has been tunneled back to a limited number of fixed (packet gateway) anchor points inside the mobile networks. This is increasingly inefficient, non-performant, and prone to bottlenecks. 5G Core standards enable dynamic placement of the anchor point (the UPF) based on the application and network’s needs. The combination of Mavenir’s widely deployed 4G/5G cloud-native Converged Packet Core solution, coupled with the MobiledgeX Edge-Cloud platform enables the UPF to be placed on different clouds from different vendors with different ownership. Service provider control, security, and privacy are maintained by a customer’s owning operator at all times, even when roaming. This architecture helps optimal placement of the application’s backend servers, enabling a superior user experience and increased network efficiency, by significantly reducing the distance the data needs to travel before it is processed.

Validated Reference Design

For this trial validation, the Mavenir 5G Core is running in Deutsche Telekom’s network. Two network and vendor-independent cloudlets, located in Germany, have been deployed as valid UPF placements in the 5G Core routing. For instance, a video application is started on a 5G phone connected to Deutsche Telekom’s 5G network in Berlin. The request is sent to the 5G Core that selects UPF placement in the Berlin cloudlet. Tunneling is established. The video request is passed to the local edge-placed video cache and delivery commences. The identical request is made in Hanover. The traffic is then established to the Hanover cloudlet and local fulfillment occurs there. The MobiledgeX Edge Cloud 3.0 platform dynamically controls the secure placement, lifecycle management, and video traffic routing of the edge-based UPF and the video application.

“This is a successful milestone for cloud-native 5G Core traffic routing, giving Deutsche Telekom the freedom to deliver a point of interconnect/local breakouts anywhere in the world, on any cloud,” says Bejoy Pankajakshan, Chief Strategy Officer, Mavenir. “Cloud-native design of 5G network functions integrated with orchestration tools makes it possible to achieve a new level of flexibility in network function placement. Automation, agility, and flexibility are at the heart of this project.”

“The MobiledgeX Edge-Cloud platform enables our operator customers to dynamically manage and allocate UPF functionality across their own cloud infrastructure independent of vendor, in roaming partners mobile networks, in private 4G/5G networks, and in public clouds, all through one pane of glass and in one trusted and secure operation,” says Sunay Tripathi, Chief Technology Officer & EVP of Engineering & Product, MobiledgeX. “Cloud-native UPF operation transforms traffic patterns in mobile operator networks, making the telecom operator the largest customer of their own edge cloud offering which is necessary to be a true cloud leader. We are very excited that Deutsche Telekom has taken the initiative to lead.”

About Mavenir:

Mavenir is building the future of networks and pioneering advanced technology, focusing on the vision of a single, software-based automated network that runs on any cloud. As the industry's only end-to-end, cloud-native network software provider, Mavenir is focused on transforming the way the world connects, accelerating software network transformation for 250+ Communications Service Providers in over 120 countries, which serve more than 50% of the world’s subscribers. www.mavenir.com

About MobiledgeX

MobiledgeX is working with global mobile operators to deliver full control over multi-cloud edge deployments. The company’s MobiledgeX Edge-Cloud platform provides a common interface for managing application workloads anywhere, abstracted from underlying infrastructure, to maintain control over data, privacy and security. It also provides device native SDK and matching engines for operator and third-party application developers to maximize performance and efficiency for cloud-native applications at the edge. MobiledgeX Edge-Cloud is proven in market today via trials, proofs of concepts and deployments that involve more than 20 global operators and a range of next-gen app developers.

MobiledgeX is an edge computing company founded by Deutsche Telekom AG and headquartered in San Jose, California. https://mobiledgex.com .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release

- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release

New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release

Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release

Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye